심혈관 임플란트 시장 보고서 : 제품 유형, 소재, 시술 방법, 적응증, 지역별(2026-2034년)

The global cardiovascular implants market size reached USD 29.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 46.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.22% during 2026-2034. The rising prevalence of cardiovascular diseases, the expanding geriatric population, and significant advancements in the healthcare sector, represent some of the key factors driving the market.

CARDIOVASCULAR IMPLANTS MARKET ANALYSIS:

• Major Market Drivers: The increasing incidences of CVDs due to sedentary lifestyles, unhealthy dietary habits, high-stress levels, and the expanding prevalence of diabetes and obesity among consumers, represent key factors driving the market growth. Moreover, the rising geriatric population who are more susceptible to medical conditions, coupled with significant advancements in healthcare infrastructure, is creating a favorable outlook for the market.
• Key Market Trends: The shifting preference for minimally invasive surgeries (MIS) due to their associated benefits, such as faster recovery and improved patient outcomes, presents remunerative growth opportunities for the market. In addition, ongoing advancements in technology, introduction of sophisticated cardiovascular implants, and extensive investments in research and development (R&D) initiatives by leading market players to develop improved product variants, are contributing to the market growth.
• Competitive Landscape: Some of the prominent cardiovascular implants market companies include BIOTRONIK SE & Co. KG, Abbott Laboratories, AMG International, B. Braun Melsungen AG, Johnson & Johnson Services, Inc., W. L. Gore & Associates, Inc., Medtronic Private Limited, Boston Scientific Corporation, Sorin Corporation, Edwards Lifesciences Corporation, Fortimedix Surgical B.V., Neovasc Inc., CryoLife Inc., Proxy Biomedical Ltd., REVA Medical, LLC., and Shree Pacetronix Ltd., among many others.
• Geographical Trends: According to the cardiovascular implants market dynamics, North America exhibits a clear dominance in the market owing to a significant burden of cardiovascular diseases (CVDs), such as coronary artery disease, hypertension, and heart failure.
• Challenges and Opportunities: Stringent regulatory compliances and high costs associated with cardiovascular implants. Moreover, advances in materials science, nanotechnology, and biocompatibility are driving the development of next-generation cardiovascular implants with improved performance and safety profiles.

CARDIOVASCULAR IMPLANTS MARKET TRENDS:

Rising Prevalence of Cardiovascular Diseases

As cardiovascular diseases, such as coronary artery disease, heart failure, and arrhythmias, continue to rise globally, there is a growing demand for cardiovascular implants to manage and treat these conditions effectively. For instance, according to an article published by the U.S. Centers for Disease Control and Prevention in 2024, one person dies every 33 seconds from cardiovascular disease. Also, in 2022 nearly 702,800 i.e., one in five people died from heart disease. Moreover, coronary heart disease is the most prevalent form of heart disease. About one in every twenty individuals aged 20 and older has CAD. These factors are expected to propel the cardiovascular implants market in the coming years.

Increasing Aging Population

The demographic shift towards an older population is a major driver of the cardiovascular implant market. For instance, according to an article published by the World Health Organization (WHO), by 2030, one in every six persons in the world will be 60 or older. At this time, the proportion of the population aged 60 and up rose from 1 billion in 2020 to 1.4 billion. By 2050, the global population of persons aged 60 and up will double (2.1 billion). Aging is associated with a higher incidence of cardiovascular diseases, necessitating interventions, such as pacemakers, defibrillators, and heart valves. For instance, according to an article published by Medline Plus, congestive heart failure affects people over the age of 75 at ten times the rate of younger adults. These factors further positively influence the cardiovascular implants market share.

Technological Advancements

Continuous innovations in cardiovascular implant technologies drive the market growth. Advances include bioresorbable stents, transcatheter heart valves (TAVR), leadless pacemakers, and implantable cardiac monitors, which offer improved efficacy, durability, and patient outcomes. For instance, in May 2024, Edwards Lifesciences launched the Sapien 3 Ultra Resilia valve in Europe. It uses bovine pericardial tissue treated with anti-calcification technology to serve as the foundation for new types of valves. The calcium-blocking method addresses structural valve degradation, which is a leading cause of reintervention following valve replacement, thereby boosting the cardiovascular implant systems market revenue.

GLOBAL CARDIOVASCULAR IMPLANTS INDUSTRY SEGMENTATION:

Breakup by Product Type:

• Coronary Stent
• ICD
• Heart Valve
• Implanted Cardiac Pacemaker
• CRT Device
• Peripheral Stent

ICD currently exhibits a clear dominance in the market

ICDs are crucial in preventing sudden cardiac death (SCD) by detecting and correcting life-threatening arrhythmias, such as ventricular tachycardia and ventricular fibrillation. This life-saving capability positions ICDs as essential devices for patients at high risk of cardiac arrhythmias. For instance, in October 2023, Medtronic plc, a global healthcare technology provider, received U.S. FDA approval for the Aurora EV-ICD MRI SureScan.

Breakup by Material:

• Metals and Alloys
• Polymers
• Biological Materials

According to the cardiovascular implants market overview, metals and alloys are used in stents due to their mechanical strength, corrosion resistance, and ability to be manufactured into intricate designs. Moreover, polymers are used in pacemaker and defibrillator leads for insulation, flexibility, and biocompatibility. Apart from this, biological materials are used in bioprosthetic heart valves, where animal (porcine or bovine) or human tissue (cadaveric) is used for valve leaflets. These valves offer improved hemodynamics and reduced risk of thrombosis compared to mechanical valves.

Breakup by Procedure Type:

• Angioplasty
• Open Heart Surgery

Angioplasty is a minimally invasive procedure used to widen narrowed or blocked arteries typically caused by atherosclerosis. It involves the use of a catheter with a balloon at its tip, which is inflated at the site of the blockage to compress the plaque against the artery walls, thereby restoring blood flow. Moreover, open-heart surgery is a surgical procedure where the chest is opened to access the heart. It is used for a variety of conditions, including coronary artery bypass grafting (CABG), valve repair or replacement, and congenital heart defect repairs.

Breakup by Indication:

• Arrhythmias
• Myocardial Ischemia
• Acute Myocardial Infarction
• Congestive Heart Failure
• Others

Arrhythmias accounted for the largest market share

Arrhythmias are common cardiac disorders affecting millions of people worldwide. They include conditions such as atrial fibrillation (AFib), ventricular tachycardia (VT), and bradyarrhythmias (slow heart rhythms). The high prevalence of these conditions necessitates a wide array of implantable devices for management and treatment.

Breakup by Region:

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America

North America accounts for the largest market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. According to the report, North America was the largest market for cardiovascular implants.

Some of the factors driving the North America cardiovascular implants market included the rising prevalence of CVDs, innovative product advancements, and the growing geriatric population. The region has a significant burden of cardiovascular diseases, such as coronary artery disease, hypertension, and heart failure. For instance, according to the Centers for Disease Control and Prevention's (CDC) updated report for 2022, the number of fatalities in the United States from heart disease was 659,041 in 2019 and grew to nearly 690,882 by 2020. The high prevalence of these conditions necessitates a range of cardiovascular implants for treatment and management. Moreover, continuous innovations in cardiovascular implant technologies, including stents, pacemakers, implantable defibrillators, and heart valves, drive the market growth. Advances such as bioresorbable stents, leadless pacemakers, and transcatheter heart valves (TAVR) improve patient outcomes and expand treatment options.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

• BIOTRONIK SE & Co. KG
• Abbott Laboratories
• AMG International
• B. Braun Melsungen AG
• Johnson & Johnson Services, Inc.
• W. L. Gore & Associates, Inc.
• Medtronic Private Limited
• Boston Scientific Corporation
• Sorin Corporation
• Edwards Lifesciences Corporation
• Fortimedix Surgical B.V.
• Neovasc Inc.
• CryoLife Inc.
• Proxy Biomedical Ltd.
• REVA Medical, LLC.
• Shree Pacetronix Ltd.

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Cardiovascular Implants Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Breakup by Product Type
• 5.5 Market Breakup by Material
• 5.6 Market Breakup by Procedure Type
• 5.7 Market Breakup by Indication
• 5.8 Market Breakup by Region
• 5.9 Market Forecast

6 Market Breakup by Product Type

• 6.1 Coronary Stent
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 ICD
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Heart Valve
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Implanted Cardiac Pacemaker
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 CRT Device
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Peripheral Stent
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast

7 Market Breakup by Material

• 7.1 Metals and Alloys
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Polymers
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Biological Materials
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Procedure Type

• 8.1 Angioplasty
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Open Heart Surgery
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Indication

• 9.1 Arrhythmias
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Myocardial Ischemia
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Acute Myocardial Infarction
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Congestive Heart Failure
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Others
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Europe
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Asia Pacific
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Middle East and Africa
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast
• 10.5 Latin America
  • 10.5.1 Market Trends
  • 10.5.2 Market Forecast

11 Global Cardiovascular Implants Industry: SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Global Cardiovascular Implants Industry: Value Chain Analysis

13 Global Cardiovascular Implants Industry: Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Global Cardiovascular Implants Industry: Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 BIOTRONIK SE & Co. KG
  • 15.3.2 Abbott Laboratories
  • 15.3.3 AMG International
  • 15.3.4 B. Braun Melsungen AG
  • 15.3.5 Johnson & Johnson Services, Inc.
  • 15.3.6 W. L. Gore & Associates, Inc.
  • 15.3.7 Medtronic Private Limited
  • 15.3.8 Boston Scientific Corporation
  • 15.3.9 Sorin Corporation
  • 15.3.10 Edwards Lifesciences Corporation
  • 15.3.11 Fortimedix Surgical B.V.
  • 15.3.12 Neovasc Inc.
  • 15.3.13 CryoLife Inc.
  • 15.3.14 Proxy Biomedical Ltd.
  • 15.3.15 REVA Medical, LLC.
  • 15.3.16 Shree Pacetronix Ltd.